22nd Century Group, Inc. Announces Allowance of U.S. Patent for MPO Nicotine Biosynthesis Gene
1/3/2013 9:02:02 AM
CLARENCE, N.Y.--(BUSINESS WIRE)--22nd Century Group, Inc. (OTCBB: XXII), a company that has developed groundbreaking technology for tobacco harm reduction and smoking cessation products, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the N-methylputrescine oxidase (MPO) gene technology. MPO is essential for production of nicotine in the tobacco plant.
comments powered by